BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 20371505)

  • 1. Effect of bosentan on skin fibrosis in patients with systemic sclerosis: a prospective, open-label, non-comparative trial.
    Kuhn A; Haust M; Ruland V; Weber R; Verde P; Felder G; Ohmann C; Gensch K; Ruzicka T
    Rheumatology (Oxford); 2010 Jul; 49(7):1336-45. PubMed ID: 20371505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist.
    Korn JH; Mayes M; Matucci Cerinic M; Rainisio M; Pope J; Hachulla E; Rich E; Carpentier P; Molitor J; Seibold JR; Hsu V; Guillevin L; Chatterjee S; Peter HH; Coppock J; Herrick A; Merkel PA; Simms R; Denton CP; Furst D; Nguyen N; Gaitonde M; Black C
    Arthritis Rheum; 2004 Dec; 50(12):3985-93. PubMed ID: 15593188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term experience of bosentan for treating ulcers and healed ulcers in systemic sclerosis patients.
    García de la Peña-Lefebvre P; Rodríguez Rubio S; Valero Expósito M; Carmona L; Gámir Gámir ML; Beltrán Gutiérrez J; Díaz-Miguel C; Orte Martínez J; Zea Mendoza AC
    Rheumatology (Oxford); 2008 Apr; 47(4):464-6. PubMed ID: 18263597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial.
    Matucci-Cerinic M; Denton CP; Furst DE; Mayes MD; Hsu VM; Carpentier P; Wigley FM; Black CM; Fessler BJ; Merkel PA; Pope JE; Sweiss NJ; Doyle MK; Hellmich B; Medsger TA; Morganti A; Kramer F; Korn JH; Seibold JR
    Ann Rheum Dis; 2011 Jan; 70(1):32-8. PubMed ID: 20805294
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blood flow in the hands of a predefined homogeneous systemic sclerosis population: the presence of digital ulcers and the improvement with bosentan.
    Meijs J; Voskuyl AE; Bloemsaat-Minekus JP; Vonk MC
    Rheumatology (Oxford); 2015 Feb; 54(2):262-9. PubMed ID: 25150178
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of the dual endothelin receptor antagonist bosentan on Raynaud's phenomenon secondary to systemic sclerosis: a double-blind prospective, randomized, placebo-controlled pilot study.
    Nguyen VA; Eisendle K; Gruber I; Hugl B; Reider D; Reider N
    Rheumatology (Oxford); 2010 Mar; 49(3):583-7. PubMed ID: 20040526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon.
    Merkel PA; Herlyn K; Martin RW; Anderson JJ; Mayes MD; Bell P; Korn JH; Simms RW; Csuka ME; Medsger TA; Rothfield NF; Ellman MH; Collier DH; Weinstein A; Furst DE; Jiménez SA; White B; Seibold JR; Wigley FM;
    Arthritis Rheum; 2002 Sep; 46(9):2410-20. PubMed ID: 12355489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bosentan treatment for Raynauds phenomenon and skin fibrosis in patients with Systemic Sclerosis and pulmonary arterial hypertension: an open-label, observational, retrospective study.
    Giordano N; Puccetti L; Papakostas P; Di Pietra N; Bruni F; Pasqui AL; Acampa M; Bocchi V; Donati V; Voglino M; Fioravanti A; Montella A; Auteri A; Nuti R; Pastorelli M
    Int J Immunopathol Pharmacol; 2010; 23(4):1185-94. PubMed ID: 21244767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bosentan improves skin perfusion of hands in patients with systemic sclerosis with pulmonary arterial hypertension.
    Rosato E; Molinaro I; Borghese F; Rossi C; Pisarri S; Salsano F
    J Rheumatol; 2010 Dec; 37(12):2531-9. PubMed ID: 20810512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Statins: potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers.
    Abou-Raya A; Abou-Raya S; Helmii M
    J Rheumatol; 2008 Sep; 35(9):1801-8. PubMed ID: 18709692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Digital ulcers in scleroderma patients: A retrospective observational study.
    De Cata A; Inglese M; Molinaro F; De Cosmo S; Rubino R; Bernal M; Mazzoccoli G
    Int J Immunopathol Pharmacol; 2016 Jun; 29(2):180-7. PubMed ID: 26684622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Longterm effects of endothelin receptor antagonism on microvascular damage evaluated by nailfold capillaroscopic analysis in systemic sclerosis.
    Cutolo M; Zampogna G; Vremis L; Smith V; Pizzorni C; Sulli A
    J Rheumatol; 2013 Jan; 40(1):40-5. PubMed ID: 23118114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bosentan for severe pulmonary arterial hypertension related to systemic sclerosis with interstitial lung disease.
    Ahmadi-Simab K; Hellmich B; Gross WL
    Eur J Clin Invest; 2006 Sep; 36 Suppl 3():44-8. PubMed ID: 16919010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of bosentan for digital ulcers related to systemic sclerosis: a real-life retrospective French study of 89 patients treated since specific approval.
    Agard C; Carpentier PH; Mouthon L; Clerson P; Gressin V; Bérezné A; Diot E; Jego P; Lok C; Sparsa A; Chatelus E; Van Kien AK; Quéré I; Sibilia J; Hachulla E
    Scand J Rheumatol; 2014; 43(5):398-402. PubMed ID: 24720440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Digital ulcers and outcomes assessment in scleroderma.
    Matucci-Cerinic M; Seibold JR
    Rheumatology (Oxford); 2008 Oct; 47 Suppl 5():v46-7. PubMed ID: 18784143
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Bosentan for treatment of active digital ulcers in patients with systemic sclerosis].
    Launay D; Diot E; Pasquier E; Mouthon L; Boullanger N; Fain O; Jego P; Carpentier P; Hatron PY; Hachulla E
    Presse Med; 2006 Apr; 35(4 Pt 1):587-92. PubMed ID: 16614599
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful treatment of systemic sclerosis-related digital ulcers and sarcoidosis with endothelin receptor antagonist (bosentan) therapy.
    Tillon J; Hervé F; Chevallier D; Muir JF; Levesque H; Marie I
    Br J Dermatol; 2006 May; 154(5):1000-2. PubMed ID: 16634913
    [No Abstract]   [Full Text] [Related]  

  • 18. Bosentan as a rescue therapy in scleroderma refractory digital ulcers.
    Chamaillard M; Heliot-Hosten I; Constans J; Taïeb A
    Arch Dermatol; 2007 Jan; 143(1):125-6. PubMed ID: 17224564
    [No Abstract]   [Full Text] [Related]  

  • 19. Effect of Bosentan on systemic sclerosis-associated interstitial lung disease ineligible for cyclophosphamide therapy: a prospective open-label study.
    Furuya Y; Kuwana M
    J Rheumatol; 2011 Oct; 38(10):2186-92. PubMed ID: 21885489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Controlling the digital ulcerative disease in systemic sclerosis is associated with improved hand function.
    Mouthon L; Carpentier PH; Lok C; Clerson P; Gressin V; Hachulla E; Bérezné A; Diot E; Van Kien AK; Jego P; Agard C; Duval-Modeste AB; Sparsa A; Puzenat E; Richard MA;
    Semin Arthritis Rheum; 2017 Jun; 46(6):759-766. PubMed ID: 28214014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.